Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 26 Oct, 19:53 UTC

Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule could offer better tolerability compared to the rest of its class. The SPAC merger taking Corxel public is expected to close in the first half of 2027, which is when the biotech…

science

Sources

• T2Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3Fierce Biotech / Fierce Healthcare / MedCity / GEN26 Oct, 19:53